M. Lanfear, President
Mr. Lanfear is the Founder and current Chairman of InteKrin Therapeutics, a private, late-stage biotechnology company. Mr. Lanfear was President and CEO of InteKrin from its founding in 2005 until May 2010. Under Mr. Lanfear’s leadership, the company went from inception through a successful End-Of-Phase-2 meeting with FDA and into Phase 3 clinical trials with a novel lead product with high market potential in the major therapeutic area of Type 2 diabetes.
Denny is a thirteen year veteran of Amgen, Inc., where he was a Corporate Officer and Vice-President with broad operational, product development and marketing responsibilities. His tenure began in 1986 as founder of the Process Development Department. Under his ten-year leadership this group became the preeminent PD organization in biopharma and an area of key strategic advantage for the company.
While at Amgen he also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more that 20 INDs and several BLAs. He also managed corporate partner relationships including those with SKB (from 1986 to 1990) and Regeneron Pharmaceuticals (from 1991 to 1999), where he had direct budgetary responsibility for the $135M development partnership. In 1997 he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.
Prior to joining Amgen, Denny held positions of increasing responsibility at Baxter International. Denny was also the founder and former CEO of Saronyx, Inc., a drug development software services company with several major biotech clients.
Mr. Lanfear is also an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor and former Director of Anthera Pharmaceuticals, Inc., which completed an initial public offering in March 2010 (“ANTH”). He was also an early investor in Corthera, sold to Novartis in 2009. He is currently a Director of Insmed Therapeutics Inc, a public company (“INSM”) which sold its biogenerics business to Merck in 2009 for $125M. Lanfear Capital is also Limited Partner in selected venture funds.
Mr. Lanfear earned degrees in Biochemistry and Chemical Engineering from Michigan State University and his MBA from the Anderson School at UCLA.